The debate over marijuana policy tends to be dominated by people with political "skin in the game," when what's needed is a balanced, evidenced-based review, said Kevin P. Hill, MD, MHS, of Beth Israel Deaconess Medical Center and Harvard Medical School.
Marijuana is now legal in some form in 29 states, including 9 states that allow recreational use. But according to psychiatrist and addiction expert Kevin P. Hill, MD, MHS, it’s not your father’s weed out there. What’s more, policy makers who fail to take an evidence-based approach when crafting laws for medical marijuana or decriminalization can leave loopholes or cause problems for their health systems.
Whether or not they agree with making cannabis legal, Hill said, it’s important that health professionals follow what’s happening so they can create policies that make sense. Hill, who recently became the director of Addiction Psychiatry at Beth Israel Deaconess Medical Center, is an assistant professor of psychiatry at Harvard Medical School and spoke Saturday at the 30th US Psychiatric and Mental Health Congress in New Orleans, Louisiana.
“You’ve heard so much about cannabis in recent years, but, unfortunately, much of what you’ve heard is distorted or flat out untrue,” said Hill. The evidence about cannabis dispels the myths that marijuana is not harmful, that it is not addictive, and that people who use it don’t suffer withdrawal, he added.
At the same time, not everyone becomes addicted, just as not everyone becomes addicted to alcohol, although about 15% of adults do. The share is less for cannabis at 9% of adults; among teenagers, it’s 17%, Hill said. There’s definitely a connection to the dose, and while marijuana does not cause anxiety, it can make it worse. In addition, regular marijuana use can boost the chances a psychosis will develop if there’s a family history.
Today’s cannabis is far more potent than what was available a generation ago, Hill said; the average tetrahydrocannabinol (THC), or psychotropic content, is 12% compared with 3% to 4% in the 1960s through the 1980s. But the perceptions about cannabis are moving in the opposite direction—as rapidly as adults are taking up the drug, the idea that it poses no risk is climbing even faster, something that worries Hill, because it’s just not true.
About 22 million people used cannabis in the past year, a number that’s doubled in the past decade. Marijuana’s connection to other drugs is evident: in substance abuse programs, Hill said, 40% of patients are being treated for alcohol, 40% for opioids, and 20% for something else.
“When you sit down with these folks and you take a careful history,” he said, “I found that about 60% of these patients would talk about a time in their lives when they were using cannabis daily for years, usually in their late teens or early 20s.”
He and other researchers are focused on several areas:
When talking about cannabis, whether it’s with a patient or in the policy arena, it’s essential to be balanced, Hill said. Too often the debate is dominated by voices who have “political skin in the game.” Marijuana is not completely harmless, but people who use it are not “doomed” either, he said. A young person who uses the drug, “feels it’s helping them in some way,” and it’s important for health professionals to acknowledge that.
Part of the challenge is that cannabis is viewed in extremes—to some it’s all bad, and to others it’s not harmful at all. Hill tries to compare cannabis to alcohol, which people know can be dangerous.
“There are different degrees of danger,” Hill said. “Cannabis, on the whole, is probably not as dangerous as alcohol or opioids. But just because cannabis may not be as dangerous as alcohol or opioids doesn’t mean it’s not dangerous.”
It’s important, for example, to understand the real effects of legalization. In Colorado, the first state to allow recreational use, marijuana use among youth has been relatively unchanged, a statistic consistent with national trends. By contrast, there’s been a 57% increase in visits to the emergency department and decreased work productivity. And, Hill said there’s been a rise in synthetic marijuana use among professional athletes, because users are trying to avoid getting caught—so they use a more dangerous product.
Crafting Better Marijuana Policy
Using Massachusetts as an example, Hill pointed out areas where policies fell short on science:
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024
January 8th 2025Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.
Read More